Promoted Content Promoted Content

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): FL-118-based Drug Conjugate

            Therapeutic Area: Oncology Product Name: FL-118

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: PinotBio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration June 03, 2021

            Details:

            The companies will combine Aptamer’s Optimer technology with PinotBio’s technology using the chemotherapeutic FL-118 compound with specific linker.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: Innovate UK

            Deal Size: $475.0 million Upfront Cash: Undisclosed

            Deal Type: Funding March 08, 2021

            Details:

            Pathios Therapeutics will team up with researchers at The University of Oxford to accelerate cancer immunotherapies targeting GPR65 on immunosuppressive macrophages.